MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee Meeting

Woolfolk Building
Conference Center East, Room 145
Jackson, MS 39201-1399

February 9, 2016
10:00am to 5:00pm

MINUTES

Committee Members Present:
Billy Ray Brown, Pharm.D.
Carol Tingle, M.D.
D. Stanley Hartness, M.D.
Deborah Minor, Pharm.D.
Geri Lee Weiland, M.D.
John Cook, M.D.
John W. Gaudet, M.D.
Maretta M. Walley, R.Ph., J.D.
Ryan Harper, Pharm.D.
Steven Dancer, R.Ph.
Wilma Johnson Wilbanks, R.Ph.

Committee Members Not Present:
Anne A. Norwood, FNP, PhD

Division of Medicaid Staff Present:
Dorthy K. Young, PhD, MHSA, Deputy Administrator Health Services
Terri Kirby, B.S.Pharm., R.Ph., Interim Pharmacy Director
Cindy Noble, Pharm.D., MPH, Pharmacist III
William Thompson, Bureau Director II, Office of Medical Services
Dell Williams, Operations Management Analyst Principal
Donna Mills, Operations Management Analyst Principal

Contract Staff/GHS Staff Present:
Chad Bissell, Pharm.D., MBA
Brent Breeding, R.Ph.
Laureen Biczak, D.O.
Shelagh Harvard
Jennifer Seymour

Other Contract Staff Present:
Leslie Leon, Pharm.D., Xerox
Ashleigh Holeman, Pharm.D., Xerox
Ben Banahan, Ph.D., University of Mississippi School of Pharmacy, MS - DUR
Shannon Hardwick, R.Ph., University of Mississippi School of Pharmacy, MS - DUR

I. Call to Order

Ms. Wilma Wilbanks, Chairperson, called the meeting to order at 10:07 a.m.

II. Introductions

Ms. Terri Kirby, Mississippi Division of Medicaid (DOM) Interim Pharmacy Director, welcomed the Pharmacy & Therapeutics (P&T) Committee and all guests in the audience.

She introduced Goold Health Systems, DOM's Preferred Drug List (PDL) and Supplemental Rebate (SR) vendor. All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

Ms. Kirby introduced DOM staff members Billy Thompson, Dell Williams, and Donna Mills. Ms. Kirby recognized DOM contractors in the audience, including Drs. Leslie Leon and Ashleigh Holeman from Xerox, and Dr. Ben Banahan and Ms. Shannon Hardwick from the University of the Mississippi School of Pharmacy's MS-DUR Program.

III. Administrative Matters

Ms. Kirby reminded guests that copies of the agenda and the public comment guidelines are available at the sign-in table. She stated that there is a separate sign in sheet for advocates and reminded guests that advocate presenters are limited to 3 minutes of general comment about a disease, not specific to a drug. She noted that industry presenters must provide their full name, drug name, identification, and company affiliation when signing in. She stated that industry presenters are allowed 3 minutes per drug and that no handouts are permitted. Presenters are requested to sign in at least 10 minutes prior to start of meeting.

Ms. Kirby stated that any documents used in the meeting that are not marked confidential and proprietary will be posted on DOM's website (www.medicaid.ms.gov) after the meeting.

Ms. Kirby reviewed policies related to food and drink, cell phones and pagers, discussions in the hallways, and emergency procedures for the building.

Ms. Kirby reviewed Committee policies and procedures. She requested that Committee members complete their travel vouchers and reviewed the contents of the folders provided to each Committee member.

Ms. Kirby stated that DOM aggressively pursues supplemental rebates. Mississippi is part of the Sovereign States Drug Consortium (SSDC) pool.

Ms. Kirby reviewed the voting procedure and reminded the Committee that, in accordance with the Mississippi Open Meetings Act, the minutes reflect each person's vote. She requested that the Chair announce the recommendation, motions, and the names of committee members making motions. The minutes for each P&T Committee meeting are posted to the DOM website (www.medicaid.ms.gov) within 30 days of the meeting. The meeting minutes will be posted no

later than March 10, 2016. Decisions will be announced no later than March 1, 2016 on the DOM website.

Ms. Kirby stated that the P&T Committee works in an advisory capacity and that DOM is responsible for final decisions related to the PDL. She reviewed the meeting process. She stated that DOM takes into account recommendations from both the P&T Committee and the clinical contractor before making a final decision. She stated that the PDL is completely updated once per year; quarterly updates are implemented throughout the year.

IV. Division of Medicaid Update

There were no updates.

V. Approval of October 20, 2015 Meeting Minutes

Ms. Wilbanks asked for additions or corrections to the minutes from the October 20, 2015 meeting. The minutes stand approved.

VI. PDL Compliance/Generic Percent Report Updates

Dr. Biczak provided an explanation of the PDL Compliance and Generic Percent reports.

A. Dr. Biczak reviewed the PDL Compliance Report; overall compliance for Q4 2015 was 96.6%.

B. Dr. Biczak reviewed the Generic Percent Report; overall generic utilization for Q4 2015 was 82.0%.

VII. Drug Class Announcements

Dr. Bissell reviewed the meeting format. Dr. Bissell introduced a new class: Iron Chelating Agents.

Dr. Bissell noted that the 2017 SSDC rebate process has started.

Dr. Bissell discussed updates to PDL based on new calculation of Federal Upper Limits (FULs) released in February. A robust clinical discussion followed.

VIII. Public Comments

Robert Firnberg, Gilead Sciences, yielded his time to the Committee.

Courtney Walker, Novo Nordisk, yielded his time to the Committee.

Brad Clay, Amgen, spoke in favor of Corlanor.

Brad Clay, Amgen, spoke in favor of Repatha.

Amy Forsythe, NP, UMC, spoke in favor of Jadenu (against Exjade)

Michelle Mattox, Sandoz, spoke in favor of Zarxio.

IX. Extracted Therapeutic Class Reviews

A. Iron Chelating Agents

GHS recommended that the following list be approved. A robust clinical discussion followed. Dr. Harper moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was adopted. The approved category is below. Initial discussion mentioned tabling the class until the May meeting but the Committee ultimately decided to accept. The Committee requested that the DUR Board review compliance. GHS will provide a retrospective utilization review at the next meeting.

Dr. Dorthy Young joined the meeting and thanked the Committee. She thanked Terri Kirby and Cindy Noble, and introduced Mary Katherine Ulmer.

PREFERRED AGENTS	NON-PREFERRED AGENTS
FERRIPROX (deferiprone) EXJADE (deferasirox)	JADENU (deferasirox)

X. New Drug/New Generic Reviews

A. Zecuity

GHS recommended that Zecuity be made a non-preferred drug in the Antimigraine Agents, Triptans category. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Gaudet seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ORAL	
RELPAX (eletriptan)	almotriptan AMERGE (naratriptan) AXERT (almotriptan) FROVA (frovatriptan) IMITREX (sumatriptan) MAXALT (rizatriptan) MAXALT MLT(rizatriptan) naratriptan rizatriptan sumatriptan TREXIMET (sumatriptan/naproxen) zolmitriptan

PREFERRED AGENTS	NON-PREFERRED AGENTS
	ZOMIG (zolmitriptan)
NASAL	
IMITREX (sumatriptan)	sumatriptan ZOMIG (zolmitriptan)
INJECTABLES	
IMITREX (sumatriptan)	sumatriptan SUMAVEL (sumatriptan)[NR]
OTHER	
	ZECUITY PATCH (sumatriptan)

B. Aristada ER

GHS recommended that Aristada ER be made a non-preferred drug in the Antipsychotics category. Dr. Minor moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ORAL	
ABILIFY (aripiprazole) SmartPA amitriptyline/perphenazine chlorpromazine clozapine SmartPA fluphenazine haloperidol SmartPA olanzapine SmartPA perphenazine risperidone SmartPA SEROQUEL (quetiapine) SmartPA SEROQUEL XR (quetiapine) SmartPA thioridazine thiothixene trifluoperazine ziprasidone SmartPA	aripiprazole CLOZARIL (clozapine) SmartPA FANAPT (iloperidone) SmartPA FAZACLO (clozapine) SmartPA GEODON (ziprasidone) SmartPA HALDOL (haloperidol) SmartPA INVEGA (paliperidone) SmartPA LATUDA (lurasidone) SmartPA NAVANE (thiothixene) olanzapine/fluoxetine SmartPA paliperidone quetiapine SmartPA REXULTI (brexpiprazole) RISPERDAL (risperidone) SmartPA SAPHRIS (asenapine) SmartPA SYMBYAX (olanzapine/fluoxetine) SmartPA ZYPREXA (olanzapine) SmartPA
INJECTABLE, ATYPICALS SmartPA	
	ABILIFY (aripiprazole) ARISTADA ER (aripiprazole lauroxil) GEODON (ziprasidone) INVEGA SUSTENNA (paliperidone palmitate) INVEGA TRINZA (paliperidone) RISPERDAL CONSTA (risperidone) ZYPREXA (olanzapine) ZYPREXA RELPREVV (olanzapine)

C. Genvoya

GHS recommended that Genvoya be made a preferred drug in the Antiretrovirals category. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr.

Harper seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
INTEGRASE STRAND TRANSFER INHIBITORS	
ISENTRESS (raltegravir potassium) TIVICAY (dolutegravir sodium)	VITEKTA (elvitegravir)
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI)	
abacavir sulfate didanosine DR capsule EMTRIVA (emtricitabine) lamivudine stavudine VIDEX SOLUTION (didanosine) VIREAD (tenofovir disoproxil fumarate) ZIAGEN (abacavir sulfate) zidovudine	RETROVIR (zidovudine) VIDEX EC (didanosine) EPIVIR (butransine) ZERIT (stavudine)
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)	
EDURANT (rilpivirine) nevirapine nevirapine ER SUSTIVA (efavirenz)	INTELENCE (etravirine) RESCRIPTOR (delavirdine mesylate) VIRAMUNE (nevirapine) VIRAMUNE ER (nevirapine)
PHARMACOENHANCER – CYTOCHROME P450 INHIBITOR	
	TYBOST (cobicistat)
PROTEASE INHIBITORS (PEPTIDIC)	
EVOTAZ (atazanavir/cobicistat) NORVIR (ritonavir) REYATAZ (atazanavir) VIRACEPT (nelfinavir mesylate)	CRIXIVAN (indinavir) LEXIVA (fosamprenavir) INVIRASE (saquinavir mesylate)
PROTEASE INHIBITORS (NON-PEPTIDIC)	
PREZISTA (darunavir ethanolate)	APTIVUS (tipranavir) PREZCOBIX (darunavir/cobicistat)
ENTRY INHIBITORS – CCR5 CO-RECEPTOR ANTAGONISTS	
	SELZENTRY (maraviroc)
ENTRY INHIBITORS – FUSION INHIBITORS	
	FUZEON (enfuvirtide)
COMBINATION PRODUCTS - NRTIs	
abacavir/lamivudine/zidovudine EPZICOM (abacavir/lamivudine) lamivudine/zidovudine TRIZIVIR (abacavir/lamivudine/zidovudine)	COMBIVIR (lamivudine/zidovudine)
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOG RTIs	
TRUVADA (emtricitabine/tenofovir)	
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOGS & INTEGRASE INHIBITORS	
GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir)	STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir) TRIUMEQ (abacavir/lamivudine/ dolutegravir)
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOGS & NON-NUCLEOSIDE RTIs	
ATRIPLA (efavirenz/emtricitabine/tenofovir) COMPLERA (emtricitabine/rilpivirine/tenofovir)	
COMBINATION PRODUCTS – PROTEASE INHIBITORS	
KALETRA (lopinavir/ritonavir)	

D. Corlanor

GHS recommended that Corlanor be made a non-preferred drug in the Beta Blockers, Antianginals & Sinus Node Agents category. Dr. Minor moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
acebutolol atenolol bisoprolol BYSTOLIC (nebivolol) Step Edit metoprolol metoprolol XL nadolol pindolol propranolol sotalol timolol	BETAPACE (sotalol) betaxolol CORGARD (nadolol) HEMANGEOL (propranolol)NR INDERAL LA (propranolol) INNOPRAN XL (propranolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) SOTYLIZE (sotalol) TENORMIN (atenolol) TOPROL XL (metoprolol) ZEBETA (bisoprolol)
BETA- AND ALPHA-BLOCKERS	
carvedilol labetalol	COREG (carvedilol) COREG CR (carvedilol) TRANDATE (labetalol)
BETA BLOCKER/DIURETIC COMBINATIONS	
atenolol/chlorthalidone bisoprolol/HCTZ metoprolol/HCTZ nadolol/bendroflumethiazide propranolol/HCTZ timolol/HCTZ	CORZIDE (nadolol/bendroflumethiazide) DUTOPROL (metoprolol/HCTZ) LOPRESSOR HCT (metoprolol/HCTZ) TENORETIC (atenolol/chlorthalidone) ZIAC (bisoprolol/HCTZ)
ANTIANGINALS	
	RANEXA (ranolazine)
SINUS NODE AGENTS	
	CORLANOR (ivabradine)

E. Zarxio

GHS recommended that Zarxio be made a non-preferred drug in the Colony Stimulating Factors category. Dr. Hartness moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was adopted. The approved category is below. This was the first Bio-similar review for the MS PDL. In a commercial market, it would offer a better price but Medicaid has a higher net price; thus the reasoning for the move to non-preferred.

PREFERRED AGENTS	NON-PREFERRED AGENTS
LEUKINE (sargramostim) NEUPOGEN Vial (filgrastim)	GRANIX (tbo-filgrastim) NEULASTA (pegfilgrastim) NEUPOGEN Syringe (filgrastim) ZARXIO (filgrastim)

F. Synjardy

GHS recommended that Synjardy be made a non-preferred drug in the Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors category. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation. Dr. Minor seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS	
	FARXIGA (dapaglifozin) INVOKANA (canagliflozin) JARDIACE (empagliflozin)[NR]
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR COMBINATIONS	
	GLYXAMBI (empagliflozin/linagliptin) INVOKAMET (canaglifozin/metformin) SYNJARDY (empagliflozin/meformin) XIGDUO (dapaglifozin/metformin)

G. Repatha

GHS recommended that Repatha be made a non-preferred drug in the Lipotropics, Other (Non-statins) category. Dr. Weiland moved to accept the recommendation. Dr. Harper seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
BILE ACID SEQUESTRANTS	
cholestyramine colestipol	COLESTID (colestipol) QUESTRAN (cholestyramine) WELCHOL (colesevelam)
	OMEGA-3 FATTY ACIDS
LOVAZA (omega-3-acid ethyl esters)	VASCEPA (icosapent ethyl)
CHOLESTEROL ABSORPTION INHIBITORS	
ZETIA (ezetimibe)	
FIBRIC ACID DERIVATIVES	
fenofibrate nanocrystallized 145mg gemfibrozil TRICOR (fenofibrate nanocrystallized) TRILIPIX (fenofibric acid)	ANTARA (fenofibrate, micronized) fenofibrate 40mg tablet fenofibrate, micronized fenofibric acid FENOGLIDE (fenofibrate) FIBRICOR (fenofibric acid) LIPOFEN (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)
MTP INHIBITOR	
	JUXTAPID (lomitapide)
APOLIPOPROTEIN B-100 SYNTHESIS INHIBITOR	
	KYNAMRO (mipomersen)
NIACIN	
niacin ER NIACOR (niacin) NIASPAN (niacin)	
PCSK-9 INHIBITOR	
	PRALUENT (alirocumab) REPATHA (evolocumab)

XI. Other Business

Ms. Kirby reviewed DOMs efforts to monitor opioid use. Dr. Noble shared information from the Medicaid National Meeting on Prescription Drug Abuse and Overdose in Washington, D.C.. Dr. Banahan shared opioid criteria tracked by the DUR Board. A robust clinical discussion followed.

Ms. Kirby reviewed new Federal Upper Limits (FULs). Dr. Young noted that a pharmacy stakeholder meeting will be convened to collect feedback prior to DOMs change to the State Plan Amendment (SPA) which addresses pharmacy reimbursement. She expressed her thanks for the provider community's patience and noted that all providers will be notified at the same time.

XII. Next Meeting Date

The next meeting of the Pharmacy & Therapeutics Committee will be held on May 10, 2016 at 10:00 a.m. in the Woolfolk Building, Conference Center East, Room 145, in Jackson, Mississippi.

XIII. Adjournment

The meeting adjourned at 11:36 a.m.

MISSISSIPPI DIVISION OF
MEDICAID

Division of Medicaid
Pharmacy and Therapeutics
Committee Meeting

February 9, 2016

10:00 A.M.

Woolfolk Building; Room 145


PUBLIC MEETING NOTICES
Mississippi Public Meeting Notices
NOTICE DETAILS
NOTICE DETAILS
State Agency: Division of Medicaid
Public Body: Division of Medicaid
Title: Pharmacy and Therapeutics Committee
Subject: Quarterly Meeting
Date and Time: 2/9/2016 10:00:00 AM
Description:
See Attached
Back
MEETING LOCATION
Woolfolk State Office Building 501 North West St Jackson MS 39201
Map this!
CONTACT INFORMATION
William (Billy) Thompson
601-359-5242
William.Thompson@Medicaid.ms.gov
DOWNLOAD ATTACHMENTS
P&T description for transparency.docx
Added 10/2/2015
SUBSCRIPTION OPTIONS
Subscription options will send you alerts regarding future notices posted by this public body.
RSS
ABOUT
Mississippi's State Agencies are required to post notices of regular meetings on the Mississippi Public Meeting Notices Website. The statute establishing this website is in Mississippi Code Section A 025-0041-0013 and may be viewed by clicking here.
Legislation
TRAINING
Training tools have been developed to assist those tasked with posting meeting notices to the site. Training information is available for users of the Public Meeting Notice Website by clicking here.
Training